Lung Cancer

Lung cancer is highly genetically diverse, and studies require a wide array of biomarkers along with comprehensive molecular profiling.

Our specialists support comprehensive lung cancer studies from discovery through phase III registration trials, providing the advanced molecular testing capabilities and regulatory expertise necessary for developing treatments that can transform outcomes for patients with this aggressive disease.

Here’s an overview of the unique solid tumour offerings at Cerba Research:

With NCCN guidelines emphasizing that ‘broad molecular profiling is a key component of the improvement of care of patients with NSCLC, the complexity of testing for EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, and PD-L1—along with emerging targets—requires a laboratory partner with unparalleled expertise in next-generation sequencing, immunohistochemistry, and FISH methodologies.

The shift toward NGS as the “most commonly used testing method” means finding the right collaborator becomes essential for navigating the intricate landscape of lung cancer biomarker detection.

Here’s how our testing capabilities support your lung cancer trials:

1.NCCN guidelines 2024; 2.Bebb et al. Curr Oncol 2021; 3.Cabillic et al. ESMO Open 2018;3(6):e419; 4.Li et al. J Nat Cancer Center 2021; †Cerba Research Data In-house mostly available through the ACTOnco®/Cerba France/Cerba US NGS panels or CR Montpellier/NY (IHC) or Cerba France (FISH); *Validation level may vary; IHC=immunohistochemistry; NGS=next-generation sequencing; FISH=fluorescence in situ hybridization